Skip to main content

Postbariatric Hypoglycemia

2
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Vogenx
VogenxNC - Durham
2 programs
2
MizagliflozinPhase 2Small Molecule1 trial
MizagliflozinPhase 2Small Molecule1 trial
Active Trials
NCT05541939Completed9Est. Feb 2023
NCT05721729Completed15Est. Jun 2025
MBX Biosciences
MBX BiosciencesCARMEL, IN
2 programs
MBX 1416PHASE_11 trial
MBX 1416PHASE_21 trial
Active Trials
NCT06036784Completed69Est. Dec 2024
NCT07029412Recruiting10Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
MBX BiosciencesMBX 1416
VogenxMizagliflozin
VogenxMizagliflozin
MBX BiosciencesMBX 1416

Clinical Trials (4)

Total enrollment: 103 patients across 4 trials

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Start: Aug 2025Est. completion: Jan 202610 patients
Phase 2Recruiting
NCT05721729VogenxMizagliflozin

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Start: Jun 2023Est. completion: Jun 202515 patients
Phase 2Completed
NCT05541939VogenxMizagliflozin

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

Start: Sep 2022Est. completion: Feb 20239 patients
Phase 2Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

Start: Sep 2023Est. completion: Dec 202469 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 103 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.